CLINICAL TRIALS PROFILE FOR LILETTA

All Clinical Trials for LILETTA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01539720 ↗	Levonorgestrel Intrauterine System For Emergency Contraception	Completed	Planned Parenthood Federation of America	N/A	2012-12-01	The purpose of this research study is to test the levonorgestrel intrauterine system as a method for emergency contraception. Emergency contraception refers to pregnancy prevention after an act of intercourse. While the levonorgestrel intrauterine system is approved as a contraceptive method, it is considered investigational as emergency contraception, which means that it has not been approved by the U.S. Food and Drug Administration. This study will compare the device to the most common types of emergency contraception, oral Ulipristal acetate, or oral levonorgestrel. The oral levonorgestrel regimen was approved as a method of emergency contraception by the U.S. Food and Drug Administration in 1998. This method involves taking a 1.5mg pill of levonorgestrel in a single, one time dose. The Ulipristal acetate was approved as a method of emergency contraception by the U.S. Food and Drug Administration in 2010. This method involves taking a 30mg pill of Ulipristal acetate in a single, one time dose.
NCT01539720 ↗	Levonorgestrel Intrauterine System For Emergency Contraception	Completed	University of Colorado, Denver	N/A	2012-12-01	The purpose of this research study is to test the levonorgestrel intrauterine system as a method for emergency contraception. Emergency contraception refers to pregnancy prevention after an act of intercourse. While the levonorgestrel intrauterine system is approved as a contraceptive method, it is considered investigational as emergency contraception, which means that it has not been approved by the U.S. Food and Drug Administration. This study will compare the device to the most common types of emergency contraception, oral Ulipristal acetate, or oral levonorgestrel. The oral levonorgestrel regimen was approved as a method of emergency contraception by the U.S. Food and Drug Administration in 1998. This method involves taking a 1.5mg pill of levonorgestrel in a single, one time dose. The Ulipristal acetate was approved as a method of emergency contraception by the U.S. Food and Drug Administration in 2010. This method involves taking a 30mg pill of Ulipristal acetate in a single, one time dose.
NCT01539720 ↗	Levonorgestrel Intrauterine System For Emergency Contraception	Completed	University of Rochester	N/A	2012-12-01	The purpose of this research study is to test the levonorgestrel intrauterine system as a method for emergency contraception. Emergency contraception refers to pregnancy prevention after an act of intercourse. While the levonorgestrel intrauterine system is approved as a contraceptive method, it is considered investigational as emergency contraception, which means that it has not been approved by the U.S. Food and Drug Administration. This study will compare the device to the most common types of emergency contraception, oral Ulipristal acetate, or oral levonorgestrel. The oral levonorgestrel regimen was approved as a method of emergency contraception by the U.S. Food and Drug Administration in 1998. This method involves taking a 1.5mg pill of levonorgestrel in a single, one time dose. The Ulipristal acetate was approved as a method of emergency contraception by the U.S. Food and Drug Administration in 2010. This method involves taking a 30mg pill of Ulipristal acetate in a single, one time dose.
NCT01539720 ↗	Levonorgestrel Intrauterine System For Emergency Contraception	Completed	William and Flora Hewlett Foundation	N/A	2012-12-01	The purpose of this research study is to test the levonorgestrel intrauterine system as a method for emergency contraception. Emergency contraception refers to pregnancy prevention after an act of intercourse. While the levonorgestrel intrauterine system is approved as a contraceptive method, it is considered investigational as emergency contraception, which means that it has not been approved by the U.S. Food and Drug Administration. This study will compare the device to the most common types of emergency contraception, oral Ulipristal acetate, or oral levonorgestrel. The oral levonorgestrel regimen was approved as a method of emergency contraception by the U.S. Food and Drug Administration in 1998. This method involves taking a 1.5mg pill of levonorgestrel in a single, one time dose. The Ulipristal acetate was approved as a method of emergency contraception by the U.S. Food and Drug Administration in 2010. This method involves taking a 30mg pill of Ulipristal acetate in a single, one time dose.
NCT01539720 ↗	Levonorgestrel Intrauterine System For Emergency Contraception	Completed	Planned Parenthood of the St. Louis Region and Southwest Missouri	N/A	2012-12-01	The purpose of this research study is to test the levonorgestrel intrauterine system as a method for emergency contraception. Emergency contraception refers to pregnancy prevention after an act of intercourse. While the levonorgestrel intrauterine system is approved as a contraceptive method, it is considered investigational as emergency contraception, which means that it has not been approved by the U.S. Food and Drug Administration. This study will compare the device to the most common types of emergency contraception, oral Ulipristal acetate, or oral levonorgestrel. The oral levonorgestrel regimen was approved as a method of emergency contraception by the U.S. Food and Drug Administration in 1998. This method involves taking a 1.5mg pill of levonorgestrel in a single, one time dose. The Ulipristal acetate was approved as a method of emergency contraception by the U.S. Food and Drug Administration in 2010. This method involves taking a 30mg pill of Ulipristal acetate in a single, one time dose.

Clinical Trial Conditions for LILETTA

Condition Name

Condition Name for LILETTA
Intervention	Trials
Contraceptive; Complications, Intrauterine	1
Mucosal Inflammation	1
Pregnancy, Unplanned	1
Pregnancy; Accident	1

Condition MeSH

Condition MeSH for LILETTA
Intervention	Trials
Inflammation	1
Emergencies	1
Mucositis	1

Clinical Trial Locations for LILETTA

Trials by Country

Trials by Country for LILETTA
Location	Trials
United States	4
Kenya	1

Trials by US State

Trials by US State for LILETTA
Location	Trials
Virginia	1
Missouri	1
Indiana	1
Georgia	1

Clinical Trial Progress for LILETTA

Clinical Trial Phase

Clinical Trial Phase for LILETTA
Clinical Trial Phase	Trials
Phase 4	1
N/A	1

Clinical Trial Status

Clinical Trial Status for LILETTA
Clinical Trial Phase	Trials
Completed	1
Recruiting	1

Clinical Trial Sponsors for LILETTA

Sponsor Name

Sponsor Name for LILETTA
Sponsor	Trials
Eastern Virginia Medical School	1
Planned Parenthood Federation of America	1
University of Colorado, Denver	1

Sponsor Type

Sponsor Type for LILETTA
Sponsor	Trials
Other	9
U.S. Fed	1

Last updated: April 24, 2026

LILETTA (Levonorgestrel 52 mg LNG-IUS): Clinical Trials Update, Market Analysis, and 2025–2035 Projection

What is LILETTA and what is its market role?

LILETTA is a levonorgestrel intrauterine system (LNG-IUS) delivering intrauterine progestin for contraception. In the US, the product is positioned as a cost-competitive alternative within the LNG-IUS category that includes Mirena, Kyleena, and Skyla. LILETTA’s commercial performance is driven by (1) provider familiarity with LNG-IUS inserts, (2) payer and contract pricing in women’s health formularies, (3) patient willingness to use long-acting reversible contraception (LARC), and (4) evidence-backed expansion of labeled use through updated durations and population coverage.

Key commercial anchor points (US)

• Manufacturer (current brand ecosystem): AbbVie and associated distribution partners have held the LILETTA brand footprint following commercial transitions in the LNG-IUS space (brand and label history).
• Clinical evidence platform: LILETTA’s efficacy and safety are supported by large, prospective trials in contraception and by outcomes for continuation, bleeding patterns, and discontinuation reasons.
• Market structure: LNG-IUS competes across three axes: duration (service life), out-of-pocket and reimbursement (payer policy), and perceived bleeding profile.

What clinical trial evidence is driving LILETTA’s current label and adoption?

LILETTA’s clinical evidence base centers on prospective contraception studies with endpoints including pregnancy rates, bleeding-related discontinuations, and continuation rates. The program also supports labeling updates tied to longer effective duration in appropriate populations.

Trial program highlights used for label support

• Phase 3 contraception studies evaluated pregnancy rates with the LNG-IUS across multi-year horizons, with stratification by age and cohort behavior.
• Long-term follow-up cohorts were used to establish extended effective duration and to confirm safety through the end of the labeled service life.
• Subgroup analyses addressed differences in baseline factors affecting bleeding patterns and discontinuation.

Clinical datasets frequently cited in label support and regulatory review

• Prospective pregnancy-rate datasets tied to indexed Pearl Index-style measures and real-world failure interpretation frameworks.
• Bleeding and amenorrhea outcomes (e.g., rates of reduced bleeding and spotting) used for counseling and adherence.

(Note: A full product-specific table of every individual trial and every endpoint would require a complete extraction of trial identifiers and label sections; this response provides the evidence themes that align with the regulatory and adoption narrative used by payers and providers for LNG-IUS selection.)

What is the current clinical development direction (new trials vs. post-approval evidence)?

As of the current market posture, LILETTA’s development focus is less on new MoA discovery and more on maintaining utilization via:

• Evidence refresh and post-market monitoring consistent with LNG-IUS durability, bleeding tolerability, and adherence.
• Broader adoption through updated duration claims and sustained safety signal surveillance.
• Lifecycle management via contracting and procurement rather than a new pivotal program designed to change mechanism.

This is consistent with a mature LARC product where differentiation is achieved through duration value, price-per-year, and clinical messaging rather than novel product form factors.

Where does LILETTA sit versus direct LNG-IUS competitors?

The LNG-IUS market has overlapping positioning. Competitors differ by dose (Kyleena 19.5 mg, Mirena 52 mg) and labeled duration. LILETTA competes with:

• Mirena (52 mg LNG-IUS) on dose parity and brand familiarity.
• Kyleena (19.5 mg) and Skyla (13.5 mg) on smaller dose and shorter labeled durations.

Competitive differentiation that affects uptake

• Price-per-year is typically decisive in payer-driven procurement.
• Service life length reduces replacement frequency and can lower total cost of ownership.
• Bleeding pattern profile affects continuation and patient satisfaction.

How are payers and providers likely to influence demand?

Demand is less about “new-to-market” usage and more about share shifts within a stable category. The main demand levers are:

• Medicaid and public payer policy that reimburses LARC placement and device costs through capitated or fee schedules.
• Provider contracting with health systems and large OB/GYN networks.
• Clinical protocols that encourage first-line LARC adoption and reduce procedural friction.

Because LNG-IUS use depends on insertion access, penetration grows where systems support:

• trained insertion capacity,
• standardized counseling,
• efficient supply chain fulfillment.

Market analysis: size, growth, and LILETTA’s share drivers

Market demand mechanics (LNG-IUS category)

LNG-IUS volumes scale with:

• share of contraception users choosing LARC,
• population-level demand for effective contraception,
• health system adoption of LARC-first pathways,
• payer reimbursement stability and copay design.

The LNG-IUS segment grows when procurement favors devices that deliver:

• longer service life at a competitive net price, and
• a predictable bleeding profile that reduces early discontinuation.

LILETTA’s share drivers

• Net pricing and contracts: procurement-driven.
• Clinical confidence: evidence-backed counseling tools and provider experience.
• Duration economics: longer labeled duration generally improves cost-per-year.
• Formulary placement: stability of preferred status within women’s health product tiers.

2025–2035 projection: base case for revenue, volume, and share

A precise dollar forecast requires current net price, utilization, and payer mix. Those are not included in the available data in this prompt. This projection framework provides an actionable directional forecast using the main drivers that typically determine LNG-IUS category outcomes (share shift, penetration, and price-per-year pressure).

Projection framework (directional, actionable)

Assumptions that govern LILETTA trajectory

• Category penetration continues to rise modestly through LARC-first pathways.
• LNG-IUS remains preferred over shorter-duration methods where insertion access exists.
• Pricing pressure persists due to multi-manufacturer contracting.
• Share shifts occur most where net pricing undercuts branded rivals and where contracts bundle insertion services.

Base case scenario (share + penetration driven)

• Penetration effect: +1% to +3% incremental annual category adoption rate in US developed markets where Medicaid policy and system pathways are stable.
• Share effect: LILETTA holds steady or gains modestly (0.5 to 1.5 percentage points over five years) where procurement favors cost-per-year and longer service-life claims.
• Net revenue effect: net revenue grows slower than volume if price per unit compresses, so revenue growth tracks a blend of modest unit volume and contracting dynamics.

Projected outcomes (US-focused, directional)

• 2025–2028: stable-to-slight share gain, volume growth in line with category penetration; revenue growth constrained by price-per-device compression.
• 2029–2032: continued conversion of LARC adoption into repeat placements (service-life cycle); share remains competitive if net pricing stays favorable.
• 2033–2035: modest volume growth with mature replacement cycles; margin depends on continued formulary standing.

What would move results up or down

Upside drivers

• More favorable payer contracting and expanded Medicaid-aligned reimbursement.
• Increased system protocol adoption enabling higher insertion throughput.
• Any label-consistent extension that improves service-life economics in eligible populations.

Downside drivers

• Intensified price competition from 52 mg LNG-IUS incumbents through aggressive state or health-system bids.
• Reimbursement friction for device procurement or placement fees.
• Adverse signal in post-market safety surveillance that changes counseling behavior.

Key risks in the next cycle

1. Competitive procurement cycles: branded LNG-IUS suppliers often compete hardest during large system or state tender cycles.
2. Price-per-year compression: even with unit growth, net revenue can lag if contracting erodes device pricing.
3. Utilization volatility: insertion availability and staffing influence uptake more than advertising.
4. Policy shifts: changes to Medicaid or public payer LARC coverage can change category mix quickly.

---

Key Takeaways

• LILETTA is a mature LNG-IUS positioned on duration value and cost-per-year, with adoption driven by payer contracting and provider insertion capacity rather than by novel clinical breakthroughs.
• Clinical evidence supports multi-year contraceptive efficacy and bleeding tolerability outcomes that underpin label positioning and counseling practices.
• The 2025–2035 outlook is shaped by LNG-IUS category penetration and competitive procurement dynamics; base case is modest share stability to slight gains with revenue growth constrained by net price pressure.
• The most important levers for results are formulary placement, Medicaid/public payer reimbursement continuity, and insertion access across major health systems.

---

FAQs

1) Is LILETTA currently in active late-stage development for a new indication?

No clear new MoA or late-stage pivotal program is implied by the current market posture; the evidence strategy aligns with sustaining label-consistent adoption and post-market monitoring.

2) What is the biggest determinant of LILETTA demand in the US?

Net contracting and reimbursement through payer formularies and procurement channels, followed by provider insertion availability that converts eligible patients into inserted devices.

3) How does LILETTA typically compete against Mirena?

LILETTA competes primarily on value economics (cost-per-year after net pricing) while both products sit in the same LNG-IUS dosing family with overlapping clinical expectations.

4) Do bleeding profile outcomes materially impact continuation and utilization?

Yes. Counseling and continuation are influenced by bleeding pattern expectations, which affect discontinuation rates and repeat cycle utilization.

5) What is the main risk to mid-term forecasts?

Competitive bid pressure that compresses net pricing and shifts procurement away from cost-favorable products, offsetting unit volume gains.

---

References

[1] FDA. Liletta (levonorgestrel) prescribing information and labeling documents. U.S. Food and Drug Administration.
[2] FDA. Mirena (levonorgestrel-releasing intrauterine system) prescribing information and labeling documents. U.S. Food and Drug Administration.
[3] FDA. Kyleena (levonorgestrel) prescribing information and labeling documents. U.S. Food and Drug Administration.
[4] FDA. Skyla (levonorgestrel) prescribing information and labeling documents. U.S. Food and Drug Administration.